JP2021533125A5 - - Google Patents

Info

Publication number
JP2021533125A5
JP2021533125A5 JP2021505638A JP2021505638A JP2021533125A5 JP 2021533125 A5 JP2021533125 A5 JP 2021533125A5 JP 2021505638 A JP2021505638 A JP 2021505638A JP 2021505638 A JP2021505638 A JP 2021505638A JP 2021533125 A5 JP2021533125 A5 JP 2021533125A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound according
acceptable salt
independently
nrc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021505638A
Other languages
English (en)
Japanese (ja)
Other versions
JP7491900B2 (ja
JP2021533125A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/070312 external-priority patent/WO2020025517A1/en
Publication of JP2021533125A publication Critical patent/JP2021533125A/ja
Publication of JP2021533125A5 publication Critical patent/JP2021533125A5/ja
Priority to JP2024080418A priority Critical patent/JP2024105611A/ja
Application granted granted Critical
Publication of JP7491900B2 publication Critical patent/JP7491900B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021505638A 2018-07-31 2019-07-29 Tlr7/8アンタゴニストおよびそれらの使用 Active JP7491900B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024080418A JP2024105611A (ja) 2018-07-31 2024-05-16 Tlr7/8アンタゴニストおよびそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862712439P 2018-07-31 2018-07-31
US62/712,439 2018-07-31
PCT/EP2019/070312 WO2020025517A1 (en) 2018-07-31 2019-07-29 Tlr7/8 antagonists and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024080418A Division JP2024105611A (ja) 2018-07-31 2024-05-16 Tlr7/8アンタゴニストおよびそれらの使用

Publications (3)

Publication Number Publication Date
JP2021533125A JP2021533125A (ja) 2021-12-02
JP2021533125A5 true JP2021533125A5 (enExample) 2022-08-08
JP7491900B2 JP7491900B2 (ja) 2024-05-28

Family

ID=67660056

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021505638A Active JP7491900B2 (ja) 2018-07-31 2019-07-29 Tlr7/8アンタゴニストおよびそれらの使用
JP2024080418A Pending JP2024105611A (ja) 2018-07-31 2024-05-16 Tlr7/8アンタゴニストおよびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024080418A Pending JP2024105611A (ja) 2018-07-31 2024-05-16 Tlr7/8アンタゴニストおよびそれらの使用

Country Status (13)

Country Link
US (1) US20210300940A1 (enExample)
EP (1) EP3830080A1 (enExample)
JP (2) JP7491900B2 (enExample)
KR (2) KR20260047300A (enExample)
CN (1) CN112513024A (enExample)
AU (2) AU2019313441B2 (enExample)
BR (2) BR122023023308A2 (enExample)
CA (1) CA3108099A1 (enExample)
IL (1) IL280479A (enExample)
MX (2) MX2021000093A (enExample)
SG (1) SG11202100818RA (enExample)
TW (3) TW202542153A (enExample)
WO (1) WO2020025517A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3889145T (pt) * 2015-12-17 2024-04-02 Merck Patent Gmbh 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários
EP4198031A1 (en) 2016-08-08 2023-06-21 Merck Patent GmbH Tlr7/8 antagonists and uses thereof
CN111511729A (zh) * 2017-12-19 2020-08-07 默克专利股份公司 Tlr7/8拮抗剂及其用途
AU2020250468A1 (en) * 2019-03-29 2021-11-04 Kinki University Use of T-type calcium channel blocker for treating pruritus
JP2022081710A (ja) * 2019-03-29 2022-06-01 ユーティアイ リミテッド パートナーシップ 関節リウマチを治療するためのt型カルシウムチャネル阻害剤の使用
WO2021052892A1 (en) * 2019-09-16 2021-03-25 F. Hoffmann-La Roche Ag Piperidinyl amine compounds for the treatment of autoimmune disease
CR20220236A (es) 2019-11-28 2022-10-03 Bayer Pharma AG Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
TW202200139A (zh) * 2020-05-14 2022-01-01 德商馬克專利公司 用於治療冠狀病毒感染之tlr7/8拮抗劑
EP4263535A1 (en) 2020-12-17 2023-10-25 Astrazeneca AB N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides
KR20230171469A (ko) 2021-04-16 2023-12-20 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
CN120603821A (zh) * 2023-01-18 2025-09-05 苏州科睿思制药有限公司 Enpatoran的晶型及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI529171B (zh) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 1,7-萘啶衍生物
ES2670550T3 (es) 2013-10-14 2018-05-30 Eisai R&D Management Co., Ltd. Derivados de quinolina selectivamente sustituidos
CN104557913B (zh) * 2013-10-28 2017-02-08 上海汇伦生命科技有限公司 吡啶并嘧啶类化合物,其制备方法和用途
MX2016006052A (es) 2013-11-12 2016-07-18 Hoffmann La Roche Pirido[4,3-b]pirazin-2-carboxamidas como agentes neurogenicos para el tratamiento de trastornos neurodegenerativos.
CN108290855A (zh) * 2015-07-01 2018-07-17 西北大学 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途
WO2017031427A1 (en) * 2015-08-19 2017-02-23 3-V Biosciences, Inc. COMPOUNDS AND METHODS FOR INHIBITING mTOR
PT3889145T (pt) * 2015-12-17 2024-04-02 Merck Patent Gmbh 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários
CN106632089B (zh) * 2016-11-04 2019-06-18 中山大学 一类喹唑啉类化合物及其制备方法与应用
ES2965044T3 (es) 2017-07-18 2024-04-10 Merck Patent Gmbh Antagonistas de TLR7/8 y sus usos
CN111801015B (zh) * 2017-12-12 2022-03-18 先正达参股股份有限公司 植物生长调节
CN111511729A (zh) 2017-12-19 2020-08-07 默克专利股份公司 Tlr7/8拮抗剂及其用途

Similar Documents

Publication Publication Date Title
JP2021533125A5 (enExample)
JP2019527718A5 (enExample)
HRP20200179T1 (hr) Spojevi heteroarila kao inhibitori irak i njihova uporaba
JP2018537501A5 (enExample)
JP2020537671A5 (enExample)
JP2019031560A5 (enExample)
CA2903285C (en) 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
JP2009511490A5 (enExample)
JP2021523221A5 (enExample)
JP2023516073A5 (enExample)
JP2017511357A5 (enExample)
JP2021523225A5 (enExample)
RU2020123151A (ru) Антагонисты tlr7/8 и их применение
HRP20201985T1 (hr) Piridonski spoj kao c-met inhibitor
JP2006515858A5 (enExample)
JP2016536364A5 (enExample)
RU2018104092A (ru) Бициклические лактамы и способы их применения
JP2017504576A5 (enExample)
HRP20161127T1 (hr) Derivati indazolil triazola kao inhibitori irak
HRP20171302T1 (hr) Makrociklički derivati piridazinona
JP2017537940A5 (enExample)
JP2007536231A5 (enExample)
RU2004121161A (ru) Замещенные 2-тио-3,5-дициано-4-фенил-6-аминопиридины и их применение
RU2018102685A (ru) СОЕДИНЕНИЯ-ИНГИБИТОРЫ TBK/IKKε И ИХ ПРИМЕНЕНИЕ
RU2017101829A (ru) Пиразоловые соединения в качестве модуляторов fshr и пути их применения